This research, spearheaded by neurologist Dr. Ahmet Arac at UCLA’s David Geffen School of Medicine, challenges the entrenched hypothesis that the dominant hemisphere is prewired for enhanced motor control. Instead, the study elucidates that the experience and practice executing complex, tool-related trajectories is what sculpts arm dominance over a lifetime. The team’s approach involved meticulous tracking of three-dimensional arm movements, employing sophisticated motion-capture technology that captures nuances of motor behavior with unprecedented precision.

The investigators enlisted healthy adult participants to perform a series of reaching tasks aimed at distinguishing innate motor skill differences from those acquired through experience. Participants reached towards targets under multiple conditions: normal reaching, reaching while burdened with a four-pound wrist weight, and reaching while manipulating a lightweight stick attached to their forearm designed to simulate tool use. This stratification allowed for parsing out mechanical difficulty from the complexity of the movement required for tool handling.

Remarkably, under the conditions of simple reaching motions, and even when physical difficulty was increased by adding weight, both the dominant and non-dominant arms performed comparably, suggesting no intrinsic superiority in motor control from one cerebral hemisphere over the other. This marked the first strong indication that the motor skill asymmetry traditionally observed arises not from biology alone but from contextual task demands.

However, when participants were required to perform reaching movements with the attached stick—mimicking the curved, intricate trajectories integral to tool use—the dominant arm outperformed its counterpart. These findings illuminate how the dominant arm’s proficiency emerges specifically through the complexity and precision necessitated by tool-related actions, which are honed through repeated practice rather than hardwired neural superiority.

In an equally illuminating second experiment, participants wrote letters and numbers using a pen held in their hand and then with a pen taped to the elbow. This innovative design disrupted habitual motor patterns by forcing individuals to attempt writing with an effector— the elbow— which none had previously trained for this fine motor task. Initially, both elbows performed equally poorly, and the dominant hand’s usual edge disappeared, underscoring that the motor advantage is context-dependent instead of neuroanatomically fixed.

Following a period of practice with elbow writing, both the dominant and nondominant elbows improved substantially, with their performance surpassing that of the nondominant hand at baseline. This demonstrates that motor skill acquisition can generalize to different effectors given adequate practice and that dominance emerges as a function of learned motor sequences rather than structural brain asymmetries alone.

Dr. Ahmet Arac emphasizes that arm dominance is an emergent property arising from the lifelong honing of complex movement patterns required particularly in handwriting and object manipulation, not because of intrinsic biomechanical or hemispheric brain control advantages. This revelation prompts a shift in our conceptual framework concerning how skilled motor control develops and how the nervous system adapts to environmental and use-dependent factors.

The implications of this research extend beyond theoretical neuroscience. For clinicians involved in stroke rehabilitation and motor skill retraining, understanding that motor dominance is experience-driven opens the possibility for targeted therapies that harness neuroplasticity to train nondominant limbs and non-traditional effectors effectively. This could lead to novel rehabilitative approaches that exploit task-specific practice rather than relying solely on presumed hemispheric functional potential.

Moreover, the study offers invaluable insights into the fundamental processes of skill learning and motor memory encoding in the brain. By revealing how complex tool-use trajectories shape motor dominance, it bridges the gap between the biology of motor control and the environmental interactions that sculpt motor capabilities throughout the lifespan. This paves the way for future investigations into the neural representations of learned motor patterns and their consolidation.

This research was conducted collaboratively with coauthor Nicolas Y.H. Jeong Lee and senior author Dr. John W. Krakauer, affiliated with Johns Hopkins University and the Santa Fe Institute, representing a confluence of expertise in neurology, motor neuroscience, and computational modeling. The study was supported by premier funding agencies, including the National Institutes of Health, the US-Israel Binational Science Foundation, NVIDIA, and UCLA’s Department of Neurology, underscoring its high scientific merit.

The full details of the research can be accessed in the peer-reviewed article titled “Arm Dominance Is an Emergent Effect of Practice Executing Complex Trajectory Shapes Required by Tools and Objects,” published in the Proceedings of the National Academy of Sciences. The study not only revolutionizes the understanding of limb dominance but also holds enormous promise for applications in neural rehabilitation, motor learning research, and the development of brain-computer interfaces.

This landmark research invites us to reconsider the intricate relationship between brain structure, motor function, and experience. It shines a light on the transformative power of practice in sculpting the way we interact with the world, highlighting that the dominion of our dominant hand is not predestined in neurons alone but is shaped and forged by a lifetime of dedicated movement and skill acquisition.

Subject of Research: People
Article Title: Arm dominance is an emergent effect of practice executing complex trajectory shapes required by tools and objects
News Publication Date: 30-Jun-2026
Web References: https://www.pnas.org/doi/10.1073/pnas.2601569123
References: Arac, A., Jeong Lee, N.Y.H., & Krakauer, J.W. Arm dominance is an emergent effect of practice executing complex trajectory shapes required by tools and objects. Proc. Natl. Acad. Sci. (2026). DOI: 10.1073/pnas.2601569123
Keywords: Neurology, Neuroscience, Brain hemispheres, Left hemisphere, Right hemisphere, Arms, Hands, Fingers, Tools, Motor control, Motor skill learning

Fragile X syndrome is rooted in a mutation of the FMR1 gene, which leads to a deficiency of the fragile X mental retardation protein (FMRP). This protein plays a crucial role in synaptic development and plasticity, essential processes for normal brain maturation and function. The absence of FMRP disrupts synaptic signaling, resulting in cognitive impairments, heightened sensory sensitivity, attention deficits, and a propensity for seizures. These neurological and behavioral manifestations make Fragile X syndrome a complex disorder that has resisted therapeutic intervention.

Leveraging advanced genetic engineering techniques, the UCLA team developed a mouse model genetically modified to lack the FMR1 gene, effectively mimicking the pathophysiology of Fragile X syndrome in humans. The researchers employed high-resolution RNA sequencing to dissect gene expression patterns within excitatory and inhibitory neurons—two fundamental classes of brain cells whose balance is critical for cognitive processing and sensory integration. This cell-type-specific approach revealed a striking upregulation of the EPAC2 gene, pinpointing it as a potential mechanistic driver of Fragile X pathology.

EPAC2, a brain-specific intracellular signaling protein involved in synaptic plasticity and memory formation, emerged as a particularly compelling therapeutic target. Unlike ubiquitous proteins, EPAC2’s predominant expression in neural tissues implies that pharmacological modulation could achieve efficacy with minimal systemic side effects, a critical consideration for long-term treatment strategies. Intriguingly, the researchers observed a progressive increase in EPAC2 expression correlating with brain maturation, suggesting that interventions targeting EPAC2 might be especially beneficial during later developmental windows in older children and adults living with Fragile X syndrome.

To validate the therapeutic potential of EPAC2 inhibition, experimental paradigms involved either genetic silencing of EPAC2 or pharmacological blockade using a specific drug compound in the Fragile X mouse model. These interventions successfully normalized aberrant neural circuit activity, restoring balance between excitatory and inhibitory signaling pathways that are typically dysregulated in the disorder. Behaviorally, treated mice demonstrated significant improvements: their hypersensitivity to tactile stimuli diminished, social interaction deficits were alleviated, and seizure susceptibility was reduced—symptom domains that profoundly affect quality of life in patients.

The implications of this study extend beyond identifying a single gene; they shed light on the intricate molecular choreography underlying Fragile X syndrome. The dual examination of excitatory and inhibitory neurons uncovered complex, and often opposing, transcriptional alterations precipitated by FMR1 loss. This nuanced understanding underscores the challenge of developing therapies capable of recalibrating neural networks rather than simply targeting isolated symptoms. EPAC2 modulation represents a sophisticated approach that directly addresses circuit-level dysfunction.

Dr. Anand Suresh, the study’s lead author, emphasized the translational significance of these findings. He noted that EPAC2’s consistent dysregulation across multiple neuron types underscores its centrality to Fragile X disease mechanisms. The ability to pharmacologically modulate EPAC2 activity, thereby reversing hallmark phenotypes of Fragile X syndrome in a preclinical model, signals a breakthrough toward viable clinical treatments.

Beyond the immediate therapeutic promise, the study leverages cutting-edge translatome profiling technology, allowing researchers to examine actively translated mRNA in specific neuron populations. This method bridges the gap between gene transcription and protein synthesis, providing a precise snapshot of functional molecular changes within the brain—a crucial advance in understanding neurodevelopmental disorders at a cellular resolution.

While this research offers hope, clinical translation remains a complex hurdle. Future investigations will need to evaluate the efficacy and safety of EPAC2-targeting compounds in human subjects, determine optimal dosing strategies, and explore potential long-term effects. The brain-specific expression of EPAC2 is encouraging, potentially mitigating off-target effects, but comprehensive pharmacodynamic and pharmacokinetic profiling will be essential.

Moreover, the revelation that EPAC2 expression increases with brain maturation challenges existing dogma that Fragile X interventions are predominantly effective only during early development. This insight opens avenues for therapeutic intervention across a broader age spectrum, potentially improving outcomes for adolescents and adults who have historically lacked effective treatment options.

This discovery arrives in a landscape where Fragile X research has been hampered by clinical trial failures despite promising preclinical data. By identifying a target rooted in fundamental synaptic biology and validated in genetically precise animal models, the UCLA researchers have charted a compelling path forward that could revive and reshape therapeutic development for Fragile X syndrome.

The significance of modulating a brain-enriched signaling pathway such as EPAC2 extends into the broader neuroscience field, providing a template for addressing other neurodevelopmental disorders characterized by synaptic dysregulation and neural circuit imbalances. It exemplifies how integrative genomics and targeted molecular biology can illuminate novel intervention points in complex brain diseases.

As the scientific community rallies to build on these findings, EPAC2 stands poised as a beacon of hope for the Fragile X community. The prospect of a drug that can recalibrate neural circuits, ameliorate debilitating symptoms, and improve cognitive and social function heralds a transformative chapter in treating genetic neurodevelopmental disorders.

Subject of Research: Animals
Article Title: Translatome profiling reveals opposing alterations in inhibitory and excitatory neurons of Fragile X mice and identifies EPAC2 as a therapeutic target
News Publication Date: 18-May-2026
Keywords: Fragile X syndrome, genetic disorders, intellectual disabilities, autism, neurodevelopmental disorders, EPAC2, synaptic plasticity, neural circuits, targeted therapy, RNA sequencing, neuroscience, brain maturation